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Objectives: The objectives of this study were to summarize antiretroviral drug concentrations in breast milk (BM)
and exposure of breast-fed infants.
Methods: This was a systematic review of pharmacokinetic studies of HIV-positive women taking antiretrovirals
that measured drugs in BM. The quality of pharmacokinetic and laboratory methods was assessed using pre-
defined criteria. Pooled ratios and 95% CIs were calculated using the generalized inverse variance method
and heterogeneity was estimated by the I2 statistic. PubMed Central, SCOPUS and LactMed databases were
searched. No date or language restrictions were applied. Searches were conducted up to 10 November 2014.
Clinical relevance was estimated by comparing ingested dose with the recommended therapeutic dose for
each drug.
Results: Twenty-four studies were included. Therewas substantial variability in the clinical and laboratorymethods
used and in reported results. Relative to maternal plasma (MP), NRTIs accumulate in BM, with BM:MP ratios (95%
CI estimates) from 0.89 to 1.21 (14 studies, 1159 paired BM and MP samples). NNRTI estimates were from 0.71 to
0.94 (17 studies, 965 paired samples) and PI estimates were from 0.17 to 0.21 (8 studies, 477 paired samples).
Relative to the recommended paediatric doses, a breast-fed infant may ingest 8.4% (95% CI 1.9–15.0), 12.5%
(95% CI 2.6–22.3) and 1.1% (95% CI 0–3.6) of lamivudine, nevirapine and efavirenz, respectively, via BM.
Conclusions: Transfer to untreated infants appears quantitatively important for some NRTIs and NNRTIs. The
pharmacokinetic methods varied widely and we propose standards for the design, analysis and reporting of future
pharmacokinetic studies of drug transfer during breastfeeding.
Keywords: ARV, mother-to-child transmission, PK
Introduction
Approximately 1.5 million HIV-positive women become pregnant
each year.1 The infection of some 400000 infants annually led the
WHO to encourage provision of efavirenz-based antiretroviral
(ARV) therapy for pregnant HIV-positive women [prevention of
mother-to-child transmission (PMTCT) options B and B+].2
Increasing numbers of women will receive ARVs throughout
breastfeeding.
In contrast to well-resourced settings,3 –5 the WHO recom-
mends exclusive breastfeeding in the developing world (since
formula feeding is associated with high infant mortality)6 de-
spite breastfeeding accounting for a significant proportion of all
mother-to-child transmissions of HIV.5 Infants of ARV recipients
who acquire HIV via breast milk (BM) have high rates of drug
resistance,7,8 limiting treatment options and shortening life.
Pharmacokinetic (PK) knowledge of ARV transfer to BM and breast-
fed infants is essential to understand the safety of prolonged
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exposure through breastfeeding and limit the development of drug
resistance.
The objectives of this study were to summarize from existing
studies of breastfeeding mothers taking ARVs: (i) ARV concentra-
tions in BM; and (ii) ARV transfer to breast-fed infants.
Methods
Wewrote the protocol for this reviewbefore starting the analysis (available
as Supplementary data at JAC Online), following PRISMA guidelines.9
Ethics
Ethics approval was not necessary for this systematic review.
Inclusion criteria
We sought to identify and analyse all studies that reported drug concen-
trations of any ARV in the BM of HIV-positive women on ARVs.
Search strategy
PubMed Central, SCOPUS and LactMed databases were searched using the
keywords ‘antiretroviral’ and ‘breast’ and ‘milk’ and subsequently by
replacing the generic term ‘antiretroviral’ with the name of each individual
agent. No date or language restrictions were applied. The proceedings of
relevant conferences and citation lists from review articles and included
paperswere searched. Searcheswere conducted up to 10November 2014.
Data extraction
Data were extracted onto an Excelw spreadsheet by C. J. W. and L. J. E.,
with differences resolved by discussion amongst all authors. For each
study, the author, date, country, study design including inclusion and
exclusion criteria, sample size, ARV regimen(s) administered to themother
and whether or not infant ARVs were administered were recorded.
Methodological rigor and reporting quality
For clinical sampling, we assessed: (i) the PK sampling strategy in terms of
number of BM samples obtained from each mother, timing of sampling
relative to birth and to maternal dosing, or whether this was unclear; (ii)
if the methods used to obtain BM were described sufficiently (volume of
milk, manual or pump-assisted expression and storage ofmilk) for another
investigator to be able to replicate the process; and (iii) whether the sam-
ples of maternal plasma (MP), infant plasma (IP) and BM were obtained at
the same time, a different time or if this was unclear.
We assessed the quality of the laboratorymethods using seven criteria:
(i) if the laboratory method was described in sufficient detail for another
investigator to be able to repeat the procedure; (ii) whether the authors
validated or referred to assay validation for the BM matrix (yes/no); (iii) if
drug was measured in whole BM, if the lipid fraction was skimmed off or if
both of these methods were used; (iv) the method of drug extraction; (v)
the choice of detection method used; (vi) if the assay sensitivity was
reported (yes/no); and (vii) if detail regarding the internal standard was
provided (yes/no).
Data analysis
Outcomes
Medians and IQRs for ARV concentrations in human BM, MP and IP were
extracted. The ratio of ARV in BM to MP (BM:MP ratio) is accepted as the
key index of BM transfer of drug;10 where this was not specifically stated,
it was calculated from median MP and BM concentrations where these
were provided. BM:MP and IP:BM ratios were only determined when MP,
BM and IP concentrations were detectable (above the assay limit of quan-
tification). Hence not all studies provided sufficient data for inclusion in the
statistical analysis or presentation in the figures.
Statistical analysis
The individual studies identified in this review provided a median and IQR
or single point estimates for drug concentrations and BM:MP ratios.
Therefore, to provide a pooled estimate for the BM:MP and IP:BM ratios,
it was necessary to assume that the ratios were normally distributed
and that the median is approximately equal to the mean. Additionally, it
is assumed that the IQR is four-thirds of the standard deviation, based on
the fact that the standard normal has its 25th and 75th percentiles
approximately two-thirds of a standard deviation away from zero.11
Having calculated an assumed mean and standard deviation for all
relevant studies, pooled estimates of each outcome were obtained via
the generalized inverse variance method. Studies without a spread meas-
ure were removed from the pooling exercise.
To estimate clinical relevance, BM concentrations were interpreted as
the percentage of the recommended infant dose12 that would be ingested
by a fully breast-fed infant. If both treatment and prophylactic doses were
available, we used the PMTCT dose reflecting that which a neonate might
typically be prescribed.Whilst not included inWHO guidelines, the FDA has
approved efavirenz use in infants aged .3 months and weighing .3.5 kg
under exceptional circumstances. Genotyping for CYP2B6metabolizer sta-
tus is strongly recommended with appropriate dose adjustment, but if not
available a dose of 100 mg would be used for a 3.5 kg infant;13 this was
used in our calculations. The standard assumption of 150 mL/kg/day
milk intake wasmade. As studies did not summarize infant weights, simu-
lations were made for infants weighing 2, 3, 4 and 5 kg. CIs for the percen-
tages were calculated using standard methodology and once again
pooled estimates were obtained using the generalized inverse variance
method with zero percentages being excluded from the pooling. CIs
were capped at 0 and 100 as true percentages are being considered,
not changes in percentages.
Heterogeneity was estimated via the I2 statistic. It was not possible to
calculate an I2 statisticwhere there is only a single study or where only one
of several studies for a drug has a measure of spread.
Results
Description of studies
Twenty-four studies (19 full text and 5 conference proceedings)
met the inclusion criteria and are summarized in Table 1. Figure 1
illustrates the information sources and search strategy. Fourteen
were PK studies nestedwithin PMTCTefficacy trials, 8 were observa-
tional PK studies and 2 were nested within early-phase clinical
trials. Nineteen studies were conducted in sub-Saharan Africa.
The individual ARVs analysed in breastfeeding mothers were
nevirapine (16 studies), zidovudine (12 studies), lamivudine (12
studies), stavudine (4 studies), lopinavir (4 studies), ritonavir (4 stud-
ies), nelfinavir (4 studies), tenofovir (2 studies), efavirenz (2 studies),
atazanavir (1 study), indinavir (1 study), abacavir (1 study) and etra-
virine (1 study).
Eight studies reported IP concentrations where the infants
were not given the same drug as the mother. A further seven
also reported IP concentrations where infants and mothers
were receiving the same drug; here, MP and BM concentrations
were retained and IP levels excluded, as drug exposures in the
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Table 1. Study population
Study population Drugs taken by mother
study country design inclusion criteria exclusion criteria size duration of ART NVP ZDV 3TC other Drugs taken by infant
Aizire46 Uganda observational ARV naive, CD4
.250 cells/mm3
multiple pregnancy; in a
clinical trial; partner
refusal
120 pairs single perinatal dose X not stated
Benaboud34 Cote d’Ivoire nested in RCT not stated (within trial
population)
not stated 5 mothers 7 days X FTC, TDF not stated
Colebunders18 Belgium observational on HAART not stated 10 mothers until after BM sampling X X X NFV, IDV ZDV single dose
Corbetta22 Malawi nested in RCT CD4 .200 cells/mm3;
infant
birth weight .2 kg
not stated 20 pairs 7 days or throughout
breastfeeding (RCT)
X X X d4T, NFV NVP single dose+ZDV/
3TC 7 days
Corbett16 Malawi nested in RCT CD4 .200 cells/mm3;
on ARVs,
infants HIV2
not stated 30 pairs delivery to end of
breastfeeding
X X LPV/r not stated
Fogel32 Malawi nested in RCT CD4 ,250 cells/mm3 not stated 52 pairs median 1.5 months at
sampling time
d4T NVP (one of three
regimens in PEPI-
Malawi trial)
Frank47 Uganda observational ineligible for HAART not stated 62 pairs single perinatal dose X NVP 2 mg/kg
Giuliano24 Mozambique observational on any PMTCT regimen not stated 40 women 28 weeks gestation–1
month post-partum
X X X NVP 2 mg/kg
Kunz20 Uganda nested in RCT not stated
(trial population)
on HAART 62 pairs single perinatal dose X NVP 2 mg/kg
Mirochnick48 USA and
Puerto Rico
Phase I ARV naive; enrolled at
.34 weeks
gestation
intercurrent illness;
significant fetal
anomaly; lab
abnormalities
3 pairs single perinatal dose X NVP 2 mg/kg
Mirochnick25 Kenya nested in RCT not stated
(trial population)
not stated 67 pairs from 34 weeks gestation
through 6 months
breastfeeding
X X X NVP 2 mg/kg
Mirochnick49 Malawi+Brazil nested in RCT not stated (trial
population)
previous TDF; condition
that might affect PK
25 mothers single perinatal dose TDF TDF 4 mg/kg on days 1,
3 and 5
Moodley29 South Africa nested in RCT ARV naive multiple pregnancy;
significant fetal
anomaly; lab
abnormalities
20 pairs from 38 weeks gestation
until 1 week
post-partum
X X 3TC 4 mg/kg bd alone or
with ZDV 2 mg/kg qds
for 1 week
Musoke50 Uganda Phase
I/II study
ARV naive; enrolled at
.34 weeks
gestation
intercurrent illness;
significant fetal
anomaly; lab
abnormalities
21 pairs single perinatal dose X NVP 2 mg/kg
Olagunjua28 Nigeria observational on EFV-based ARV;
exclusively
breastfeeding
not stated 51 pairs not stated X EFV, FTC,
TDF
not stated
Palombi23 Malawi nested in RCT not stated
(trial population)
lab abnormalities 66 pairs from 25 weeks gestation
until end of
breastfeeding
X X X d4T, LPV/r NVP 2 mg/kg
Rezk31 Malawi nested in RCT on HAART not stated 60 women not stated X X X d4T, NFV,
LPV/r
not stated
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infant would reflect both orally administered drug and BM trans-
fer, making it impossible to determine the contribution from the
mother via BM. In two studies, infant blood sampling was per-
formed at intervals over a period of several months; in this case,
we included in the analysis only timepoints where the directly
administered infant drug would have no longer been detectable
based on the known ARV elimination half-life.
Study design
The PK study design, types of matrices analysed (MP, BM and IP)
and the laboratory methods are described in Tables S1 and S2.
PK design
For BM PK, 13 studies utilized a sparse PK sampling strategy (a sin-
gle timepoint within a dosing interval), with sampling either within
the first 6 weeks of life (6 studies) or at intervals up to 6 months of
age (7 studies). Two studies undertook a rich PK profile on BM,
sampling at 0, 2, 5, 8 and 24 h relative to dosing,14,15 and two fur-
ther studies performed truncated rich PK analysis from 0 to 6 h
post-dose.16,17 In seven studies, the PK design was not clear.
Fifteen studies sampled all three matrices (MP, BM and IP),
whereas 9 did not include infant concentrations. Twenty studies
sampled the different matrices contemporaneously and 3 did
not; in the final study, this was not clear (Table S1).
Methods to obtain and process BM
Nine studies provided detail on the clinical process of BM sampling
(Table S1). Regarding the fraction of milk analysed, three studies
reported the measurement of drug in BM with the lipid layer
skimmed off, six reported measurement in whole BM (one of
which specified that this was homogenized prior to extraction)18
and three studies considered both whole and skimmed BM. In
the remaining 12 studies, the milk fraction was not specified
(Table S2).
Quality of laboratory methods
Weevaluatedwhethermatrix-specific assay validation for BMwas
described, in accordance with FDA bioanalysis guidelines.19 The
majority of methods were either LC-MS or HPLC with ultraviolet
detection based; one study employed GC-MS. Two studies
described the use of drug-free milk for use in assay optimiza-
tion.20,21 Fourteen studies described assay validation or refer-
enced validated methods. Fourteen studies specified the assay
sensitivity in terms of the lower limit of quantification and eight
studies specified the internal standard used (Table S2).
Disposition of ARVs into BM and infant
The ARV concentrations in MP and BM and the corresponding
BM:MP ratios for each class of drug are summarized in Figures 2–4.
Data on infant ARVconcentrations resulting from BM exposure are
summarized in Figure 5. Figure 6 illustrates the percentage of
recommended infant dose ingested by a fully breast-fed 3 kg
infant; results for other weights were similar and are not pre-
sented here.Ru
ff
a
1
7
H
ai
ti
ob
se
rv
at
io
n
al
n
ot
st
at
ed
n
ot
st
at
ed
6
w
om
en
si
n
gl
e
d
os
e
X
n
o
Sc
h
n
ei
d
er
2
7
Rw
an
d
a
n
es
te
d
in
RC
T
.
4
5
d
ay
s
si
n
ce
d
el
iv
er
y
n
ot
st
at
ed
1
3
pa
irs
fr
om
2
8
w
ee
ks
ge
st
at
io
n
u
n
ti
l6
m
on
th
s
po
st
-p
ar
tu
m
X
X
X
EF
V
N
V
P
2
m
g/
kg
st
at
+
ZD
V
4
m
g/
kg
fo
r
7
d
ay
s
Sh
ap
iro
4
5
Bo
ts
w
an
a
n
es
te
d
in
RC
T
n
ot
st
at
ed
(t
ria
lp
op
u
la
ti
on
)
n
ot
st
at
ed
5
0
pa
irs
fr
om
2
4
–
3
6
w
ee
ks
ge
st
at
io
n
,t
h
ro
u
gh
ou
t
br
ea
st
fe
ed
in
g
X
X
X
A
BC
,L
PV
/r
N
V
P
6
m
g,
ZD
V
4
m
g/
kg
bd
fo
r
4
w
ee
ks
Sh
ap
iro
3
0
Bo
ts
w
an
a
n
es
te
d
in
RC
T
on
H
A
A
RT
n
ot
st
at
ed
2
0
pa
irs
.
6
w
ee
ks
X
X
X
ZD
V
4
–
6
m
g
td
s
Sp
en
ce
ra
1
5
U
SA
ob
se
rv
at
io
n
al
on
H
A
A
RT
n
ot
st
at
ed
7
w
om
en
n
ot
st
at
ed
X
X
AT
V
n
ot
st
at
ed
Sp
en
ce
ra
1
4
U
SA
ob
se
rv
at
io
n
al
st
ab
le
on
H
A
A
RT
;
u
n
d
et
ec
ta
bl
e
vi
ra
ll
oa
d
n
ot
st
at
ed
9
w
om
en
po
st
-p
ar
tu
m
d
ay
s
1
–
1
4
ET
R
n
ot
st
at
ed
W
ei
d
le
5
1
Ke
n
ya
n
es
te
d
in
RC
T
n
ot
st
at
ed
(t
ria
lp
op
u
la
ti
on
)
n
ot
st
at
ed
2
6
pa
irs
3
4
w
ee
ks
ge
st
at
io
n
to
6
m
on
th
s
po
st
-p
ar
tu
m
N
FV
n
ot
st
at
ed
N
V
P,
n
ev
ir
ap
in
e;
EF
V
,e
fa
vi
re
n
z;
ET
R
,e
tr
av
ir
in
e;
ZD
V
,z
id
ov
u
d
in
e;
3
TC
,l
a
m
iv
u
d
in
e;
d
4
T,
st
av
u
d
in
e;
TD
F,
te
n
of
ov
ir
;F
TC
,
em
tr
ic
it
ab
in
e;
A
B
C,
ab
ac
av
ir
;
AT
V
,a
ta
za
n
av
ir
;
ID
V
,i
n
d
in
av
ir
;
LP
V
/r
,r
it
on
av
ir-
bo
os
te
d
lo
pi
n
av
ir;
N
FV
,n
el
fin
av
ir;
RC
T,
ra
n
d
om
iz
ed
co
n
tr
ol
le
d
tr
ia
l;
bd
,t
w
ic
e
d
ai
ly
d
os
in
g;
td
s,
th
re
e
ti
m
es
d
ai
ly
d
os
in
g;
qd
s,
fo
u
r
ti
m
es
d
ai
ly
d
os
in
g;
st
at
,s
in
gl
e
d
os
e.
a
Co
nf
er
en
ce
pr
oc
ee
d
in
g.
Systematic review
1931
JAC
 by guest on July 7, 2015
http://jac.oxfordjournals.org/
D
ow
nloaded from
 
NNRTIs
Seventeen studies reported on NNRTI levels in MP and BM, of
which 14measured nevirapine, 2 measured efavirenz and 1mea-
sured etravirine.
Despite considerable heterogeneity (I2¼95%), studies evalu-
ating nevirapine transfer into BM consistently showed a BM:MP
ratio of ,1, with an overall pooled estimate of 0.73 (95% CI
0.71–0.76). Furthermore, three studies reported nevirapine
levels in MP and BM at several timepoints post-delivery, demon-
strating the BM:MP ratios to be relatively constant from 6 to
24 weeks post-partum, although numbers sampled at each
timepoint were small.22 –24 Eleven reporting IP nevirapine con-
centrations were confounded by administration of nevirapine
to the infant. However, both Mirochnick et al.25 and Palombi
et al.23 performed longitudinal analyses on MP, BM and IP;
given the half-life of 30 h for nevirapine in infants from a similar
population,26 by 3 months we presumed that detectable infant
levels reflected BM transfer of drug. Both studies reported similar
IP concentrations of 12% of MP at 14 weeks and ,5% by
24 weeks.23,25
Both studies of efavirenz reported BM levels lower than plasma
levels. The ratio of IP to BMwas 0.24 in one study27 and 0.08 in the
other.28 Etravirinewas found to accumulate in the breast, with the
BM:MP ratio rising from 1.09 to 3.27 between days 5 and 14 post-
partum. Infant etravirine levels were not measured.
NRTIs
Fourteen studies reported NRTI levels in MP and BM, of which 10
measured lamivudine, 7 measured zidovudine, 3 measured stav-
udine, 2 measured tenofovir, 1 measured abacavir and 1 mea-
sured emtricitabine.
Seven of 10 studies showed lamivudine accumulation in
the breast, with a median BM :MP ratio of .1, although the
variability both within and between studies was notable
(I2¼98%). The remaining three studies23,29,45 found that lamiv-
udine BM:MP ratios were ,1. The overall pooled estimate was
0.93 (95% CI 0.89–0.98). The majority of studies15,16,23 – 25
demonstrated the BM :MP ratios were constant from delivery
throughout post-partum. However, in studies that performed
intensive PK sampling,15,16 there was evidence of differential
PK within the MP and BM compartments; a slower elimination
rate of lamivudine was observed in BM than in MP, which
resulted in a gradual increase in the BM:MP ratio across the dos-
ing interval. Breastfeeding infants also had measurable drug,
with IP concentrations between 2% and 6% of MP.22,23,30
Infant lamivudine exposures and corresponding IP :BM ratios
declined over the course of the post-partum period, in spite of
a constant delivery of drug through BM, which potentially
reflects maturation (or ontogeny) of the infant’s metabolic
clearance system. Two studies evaluated MP and BM levels of
zidovudine and lamivudine at intervals up to 24 weeks post-
partum,22,23 finding the BM:MP ratios of these drugs to remain
constant over this time.
Regarding zidovudine, three studies reported lower concentra-
tions in BM compared with MP,15,23,25 three described higher
levels16,30,31 and the final study24 demonstrated wide interindivi-
dual variability in the BM:MP ratio. The overall pooled estimate
was 0.80 (95% CI 0.76–0.85). Infant levels of zidovudine were
determined in three studies.16,23,25 Zidovudine was measurable
at the time of delivery (potentially a reflection of transplacental
passage of drug), but was largely undetectable in IP after the neo-
natal period had passed.
Three studies report stavudine BM :MP ratios of .123,31,32
with a pooled estimate of 1.21 (1.07–1.36), which is signifi-
cantly .1; however, infant concentrations approached the
lower limit of quantification with a median value of zero.23,32
Two studies have measured tenofovir in BM. In one, tenofovir
was measurable in the BM of only 4 out of 25 women sampled
and neither study reported corresponding MP or IP concentra-
tions.33,34 A single study measured emtricitabine in BM, but
not MP. Abacavir had a reported BM:MP ratio of 0.85 in a single
study, but BM, MP and IP concentrations were not reported.45
PIs
Eight studies reported on PI levels in BM. One study measured ata-
zanavir, one indinavir, four lopinavir used in combination with low-
dose ritonavir and four nelfinavir. In all cases, the low-dose ritonavir
was used as a boosting agent for lopinavir. Overall penetration of
these PIs into BM was low (,40%) relative to MP. Only indinavir
was found to accumulate in BM and this studymust be interpreted
with caution since the sampleswere drawn froma singlemother on
five consecutive days.18 Of the five studies analysing infant concen-
trations of PIs, four reported levels below the limit of quantification.
One study fromMalawi was able to detect lopinavir and ritonavir in
the plasma of breast-fed infants, at 2% of MP levels.23
Records identified through
database searching
(PubMed, SCOPUS, LactMed)
(n = 443)
Additional records identified
through other sources
(conference proceedings
and cited papers)
(n = 10)
Records after duplicates removed
(n = 297)
Records screened
(n = 297)
Records excluded
(n = 249)  
Full-text articles (or
conference abstracts)
assessed for eligibility
(n = 48)
Full-text articles excluded,
with reasons
(n = 24)
Editorial or Review Article (10)
Methodology Papers (3)
Studies not measuring ARVs in
BM (7)
Study involving a single
participant (1)
Conference paper with data
identical to that in subsequent
full manuscript (3)
Studies included in
qualitative synthesis
(n = 24)
19 full papers; 5 abstracts
Figure 1. Information sources and search strategy.
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Drug Study
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(weeks)
MP
(ng/mL)
BM
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Aizire_2012NVP
Colebunders_2005
Corbett*_2008
Corbett*_2008
Corbett*_2008
Frank_2012
Giuliano_2007
Giuliano_2007
Kunz_2009
Mirochnick_1998
Mirochnick_2009
Musoke_1999
Rezk_2008
Ruff*_1994
Palombi_2012
Palombi_2012
Palombi_2012
Palombi_2012
Shapiro_2005
Spencer*_2014
Spencer*_2014
0.7
2
Shapiro_2012
EFV
ETR
Schneider_2008
Olagunju*_2014
NR
16
299
196
6030
2310
241
797
3450
2280
79
79
0 0.5 1 1.5 2
BM:MP ratio
2.5 3 3.5 4
13
I2 = 95%
I2 = NA
I2 = NaN%
51
1
NR
6
12
24
0–2
0
1
NR
NR
NR
NR
NR
NR
0
4
14
24
NR
NR
171
NR
1904
3992
2279
3670
2900
4000
164
NR
6087
1644
NR
747
4843
5677
5534
5349
9534
6710
112
NR
1305
3420
1220
2180
2500
2100
114
NR
4564
454
NR
931
2206
3311
3143
2881
6795
1830
51
34
8
7
6
62
40
36
62
3
153
20
39
6
39
52
45
45
20
15
Figure 2. Forest plot of BM:MP ratios for NNRTIs. Mean (SD) BM:MP ratios are illustrated for each drug. Where studies reported drug levels measured at different infant ages (representing
different sampling times post-partum), these are represented as a separate line. The vertical line indicates a BM:MP ratio of 1, where BM and MP levels are equal. Pooled statistics are
shown by the diamond and the I2 statistic is indicated. NVP, nevirapine; EFV, efavirenz; ETR, etravirine; NR, not reported; NaN, not a number; NA, not available. *Conference proceeding.
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Figure 3. Forest plot of BM:MP ratios for NRTIs. Mean (SD) BM:MP ratios are illustrated for each drug. Where studies reported drug levels measured at different infant ages (representing
different sampling times post-partum), these are represented as a separate line. The vertical line indicates a BM:MP ratio of 1, where BM and MP levels are equal. Pooled statistics are
shown by the diamond and the I2 statistic is indicated. 3TC, lamivudine; ZDV, zidovudine; d4T, stavudine; ABC, abacavir; NR, not reported; NA, not available. *Conference proceeding.
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Figure 4. Forest plot of BM:MP ratios for PIs. Mean (SD) BM:MP ratios are illustrated for each drug. Where studies reported drug levels at different infant ages (representing different
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Figure 5. Forest plot of IP:BM ratios for all drugswhere infant concentrationswere detectable, grouped according to drug class.Where studies reported drug levels at different infant ages,
these are represented as a separate line. Pooled statistics are shown by the diamond and the I2 statistic is indicated. EFV, efavirenz; NVP, nevirapine; 3TC, lamivudine; ZDV, zidovudine; LPV,
lopinavir; RTV, ritonavir; NR, not reported; NA, not available. *Conference proceeding.
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Figure 6. ‘Dose’ via BM to a fully breast-fed 3 kg infant, as a percentage of recommended paediatric dose. Pooled statistics are shown by the diamond and the I2 statistic is indicated. EFV,
efavirenz; NVP, nevirapine; 3TC, lamivudine; d4T, stavudine; ZDV, zidovudine; LPV, lopinavir; RTV, ritonavir; NaN, not a number. *Conference proceeding.
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Discussion
Although increasing numbers of countries have adopted WHO
option B+, meaning that all pregnant and breastfeeding women
will receive lifelong ART,2 understanding of the PK of transfer
between mother and infant remains incomplete. Target concen-
trations have not been defined for any ARV in BM and many stud-
ies utilized an in vitro IC50 or IC95 with correction for protein
binding. These approaches are not standardized and do not
incorporate the active intracellular metabolites of NRTIs.35,36
Thus, we chose not to incorporate comparison against IC50 in
the formal undertaking of this systematic review.
The NRTIs have higher and more variable BM penetration than
the NNRTIs or PIs. Lamivudine has the highest accumulation in
the BM and reaches detectable levels in the infant. Initially
assumed to have unlikely clinical significance30 (exposure 5% of
IC50
37), more recent analysis of infants who acquired HIV through
breastfeeding in the Kisumu Breastfeeding Study (KiBS) (mothers
received zidovudine, lamivudine and either nevirapine or nelfinavir)
found more than three-quarters to have resistance to both nevira-
pine and lamivudine.7 Further, amongst mothers who initiated tri-
ple therapy post-partum on the basis of clinical need in the PEPI-
Malawi trial, almost one-third of HIV-positive infants were found
to have multiclass drug resistance.8 The accumulation of zidovu-
dine in BM was also highly variable between studies, but in most
cases infant levels were undetectable, possibly attributed to the
drug’s rapid elimination half-life (1 h). Tenofovir and emtricitabine
are measurable in BM, although the relationships with maternal
and IP concentrations remain poorly defined; furthermore, tenofo-
vir is not recommended for use in children aged ,2 years. These
findings have clinical and programmatic significance. Zidovudine
and lamivudine remain components of first-line PMTCT and ARV
regimens in low-resource settings and tenofovir and emtricitabine
are increasingly used with implementation of WHO 2013
guidelines.38
Despite being a first-line ARV in PMTCT,38 only two studies
assessed efavirenz concentrations in BM. These showed infant
levels approach the minimum levels considered necessary for
effective treatment in adults, reaching 13%27 and 8%39 of MP
concentrations. No data about effective efavirenz levels necessary
for protection of neonates by PMTCTare published. In part, this is a
consequence of efavirenz having been contraindicated in preg-
nancy until 2012 due to teratogenicity concerns, which have
recently been refuted bymeta-analysis of exposed pregnancies;40
additionally, the drug is not recommended for use in children
aged ,3 years or weighing ,10 kg except under exceptional cir-
cumstances and ideally with pharmacogenomic testing.13 Even
with the extension to FDA licensing for young infants, current
guidelines state it should not be used in infants aged,3 months.
The studies by Schneider et al.27 andOlagunju et al.28 indicate that
the ‘dose’ received by the breast-fed infant may reach 3.5% of the
paediatric dose. The consequences of this in the neonatal period
and the influence of maternal and infant pharmacogenomics on
the concentrations reached warrant further evaluation.
The clinical relevance of ARV concentrations in BM is not fully
understood. Whilst high levels have been correlated with reduc-
tions in the BM viral load, reducing the amount of virus to which
the infant is exposed,24 differential accumulation of agents used
within a triple-therapy regimen risks exposure to monotherapy
within the compartment of the breast, potentially selecting
resistant HIV strains. Furthermore, transfer of low levels of individ-
ual drugs to a breast-fed HIV-positive infant is associated with
high rates of drug resistance as demonstrated in secondary ana-
lyses of both KiBS7 and PEPI-Malawi.8 Future studies should con-
sider not only the levels of each individual drug, but also the
optimal combination to be used to maximize benefits and reduce
risks.
The wide variability within and between studies may result
from differences in sampling time relative to dose, differences in
drug concentration assays and the statistical method used to
report concentrations below the lower limit of quantification, in
addition to biological differences between populations. However,
it is noted that variability was particularly marked for the NRTIs.
Intensive PK data suggest there is a possible lag in the elimination
of lamivudine (and to a lesser extent zidovudine) from BM, as
shown by a gradual increase in the BM:MP ratios over the course
of the dosing interval. This may, in part, explain the extensive vari-
ation in NRTI BM:MP ratios across studies, as sparse samples are
taken at different times relative to dosing.
The accumulation of PIs in BM is low. Protein binding is the
strongest predictor of drug transfer in BM,41 which explains
lower levels of PIs penetrating BM compared with the other
classes of drug (30% protein binding for zidovudine and lamiv-
udine compared with .90% for the PIs).42 Maternal covariates
influencing the variability in BM elimination of ARVs are poorly
defined, but may include clinical states affecting circulating
plasma proteins, such as intercurrent illness and poor nutrition.
Limitations
Statistical limitations
There are a number of limitations to the analysis. A normal distri-
bution is assumed when converting medians and IQRs to means
and standard deviations and comparison of pooled estimates
must be made with caution. Significant heterogeneity was
observed with CIs that frequently do not overlap (Figures 2–5),
necessitating restriction of analyses to the generalized inverse
variance method (use of a random-effects model43 is an alterna-
tive approach).
We have presented a pooled estimate for every drug, which has
an associated measure of spread. However, in some cases this
means we are presenting a pooled estimate for a single study,
which somemay consider as not being meaningful. This is related
to the limited data available.
The analysis of infant drug concentrations as a percentage of
the recommended paediatric dose (Figure 6) relied on several
assumptions. The source publications did not state infant weight
and quantifying the volume of milk intake is challenging—we
used the standard assumption of 150 mL/kg/day BM intake.
Furthermore, most BM concentrations reflected a single timepoint
during the dosing interval whereas the majority of mothers were
taking a twice-daily regimen; our calculations assume a stable
concentration of drug in BM throughout the dosing interval.
Finally, we used an unlicensed efavirenz dose, which remains con-
traindicated in infants aged ,3 months.
Limitations of reported methods
Although validated methods are essential for accurate and reli-
able drug concentration data,44 published clinical PK studies of
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ARVs in breastfeeding mother/infant pairs rarely report detail.
Descriptions of sample collection, fraction of milk analysed,
extraction method, type of internal standard, stability, matrix
effects, recovery, accuracy and precision are frequently lacking.
The complexity of BM, particularly relating to variable lipid and
protein content, requires that extraction methods are carefully
validated. Among the studies reported here, most authors did
not specify the milk fraction analysed or the extraction method
used. This information is essential. Whereas Fogel et al.32 reported
no significant difference in stavudine levels between whole and
skimmed milk, Shapiro et al.45 noted significantly different recov-
eries of drug between skimmed and whole BM and consequently
elected to report whole milk concentrations.30,45 Physicochemical
principles influence the partitioning of drug into aqueous or lipid
fractions of milk, but both are ingested by the infant and therefore
whole milk is more likely to reflect the true clinical situation.
The majority of BM PK studies included in this review followed
the stringent eligibility criteria of the PMTCT trial within which they
were nested. This selection process, rather than recruitment
under operational conditions, may have excluded women with
covariates influencing BM elimination of ARVs.
Studies report BM concentrations of only 13 of the currently
available ARVs. At the point of licensing, new drugs will not have
been assessed in pregnant and breastfeeding populations.
Whereas in well-resourced settings formula feeding is an option
for mothers on these drugs, validated methodology is essential
to enable investigation of BM elimination of drugs intended for
widespread use in low-resource populations where prolonged
breastfeeding is the norm.
To yield precise, high-quality data in an efficient manner, the
proposed study of a novel ARV in breastfeeding mother/infant
pairs can be informed by the findings of this review as summar-
ized in Table 2.
Conclusions
This systematic review reveals that the NRTI and NNRTI classes of
ARVs are eliminated in the BM of HIV-positive women and trans-
ferred to breastfeeding infants, which may explain the develop-
ment of drug-resistant HIV in infants where maternal ARVs have
failed to prevent transmission. Available data are drawn from a
small number of diverse studies employing laboratory method-
ology, which is frequently incompletely validated. Adoption of
recent WHO guidelines will dramatically increase the use of
ARVs in women of childbearing age in low-resource settings.
Evaluation of the PK of both existing and novel drugs in breast-
feeding mother/infant pairs is a matter of priority in order that
best practice and safety can be ensured as novel regimens are
rolled out.
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sampling schedule optimal sampling schedule to be considered from known PK of drugs
sample size determined to enable estimation of PK parameters with a high degree of precision; rational basis from previous
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